The challenges and pitfalls of incorporating evidence from cardiovascular outcomes trials in health economic modelling of type 2 diabetes
Sign Up to like & getrecommendations! Published in 2022 at "Diabetes"
DOI: 10.1111/dom.14917
Abstract: The clinical evidence base for evaluating modern type 2 diabetes interventions has expanded greatly in recent years, with numerous efficacious treatment options available (including dipeptidyl peptidase‐4 inhibitors, glucagon‐like peptide‐1 receptor agonists and sodium‐glucose cotransporter‐2 inhibitors).… read more here.
Keywords: evidence; type diabetes; outcomes trials; modelling type ... See more keywords
Classification of Deaths in Cardiovascular Outcomes Trials: Known Unknowns and Unknown Unknowns
Sign Up to like & getrecommendations! Published in 2019 at "Circulation"
DOI: 10.1161/circulationaha.118.038359
Abstract: In 2002, Donald Rumsfeld, then US Secretary of Defense, famously stated “There are known knowns. There are things we know that we know. There are known unknowns. That is to say, there are things that… read more here.
Keywords: unknown unknowns; known unknowns; outcomes trials; deaths cardiovascular ... See more keywords
Measuring outcomes in trials of interventions for people who self-harm: qualitative study of service users' views
Sign Up to like & getrecommendations! Published in 2020 at "BJPsych Open"
DOI: 10.1192/bjo.2019.93
Abstract: Background Patients often have very different ideas from clinicians about what they want treatments to achieve. Their views on what outcomes are important are not always reflected in trials. Aims To elicit the views of… read more here.
Keywords: outcomes trials; measuring outcomes; trials interventions; self harm ... See more keywords
1548-P: Changes in Glucose-Lowering Medication Use in the Era of Cardiovascular Outcomes Trials: Risk/Treatment Paradox Persists
Sign Up to like & getrecommendations! Published in 2020 at "Diabetes"
DOI: 10.2337/db20-1548-p
Abstract: Three new classes of glucose-lowering drugs were introduced into practice over the past 15 years: DPP-4 inhibitors, GLP-1 receptor agonists, and SGLT2 inhibitors. These drugs have low hypoglycemia risk, do not cause weight gain, and… read more here.
Keywords: glp 1ra; use; outcomes trials; hypoglycemia ... See more keywords